Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 14/20 | 0.81 |
| ▸ | SSTR2 | P30874 | 14/20 | 0.81 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.81 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.73 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octreotide SCHEMBL19232283 | 0.90 | SSTR2 (1.00) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| Octreotide SCHEMBL17404481 | 0.90 | SSTR2 (1.00) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| SCHEMBL22388805 | 0.90 | SSTR5 (0.94) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| Octreotide SCHEMBL23424109 | 0.90 | SSTR2 (1.00) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| Octreotide SCHEMBL17404626 | 0.90 | SSTR2 (1.00) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| SCHEMBL23482741 | 0.90 | SSTR5 (0.94) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| Octreotide SCHEMBL21840389 | 0.90 | SSTR2 (1.00) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| Octreotide SCHEMBL21944070 | 0.90 | SSTR2 (1.00) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| Octreotide SCHEMBL15856937 | 0.90 | SSTR2 (1.00) | SSTR5SSTR2SSTR4SSTR1SSTR3 | |
| Octreotide SCHEMBL15932939 | 0.90 | SSTR2 (1.00) | SSTR5SSTR2SSTR4SSTR1SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200262871-A1 | SOMATOSTATIN PRODRUGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262871-A1 | SOMATOSTATIN PRODRUGS | VIP, SSTR4, SSTR5 | SSTR5 3/4885SSTR2 6/4885SSTR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.